10.02.14
Lafayette, Calif.-based Providence Medical Technology Inc. has been issued three new patents by the U.S. Patent and Trademark Office: 8,834,530, cervical distraction method; 8,834,472, vertebral joint implants and delivery tools; and 8,828,062, vertebral joint implants and delivery tools.
“We are proud of our growing patent portfolio protecting our innovative suite of cervical fusion products,” commented Jeff Smith, CEO of Providence Medical Technology. “We believe that our method of accessing the posterior aspect of the cervical spine is unique, and that placement of implants, regardless of design, via this approach is an area of significant differentiation for our product line.”
These new issuances bring the total number of patents issued to Providence to 13.
The patent descriptions are:
• 8,834,530: Cervical distraction method describes a method of implanting an implant in a facet joint, including puncturing an access hole in a facet capsule, accessing the facet joint with a guide tool through the access hole, and routing an implant into the joint along the guide tool.
• 8,834,472: Vertebral joint implants and delivery tools describes a system for minimally invasively accessing a spinal facet joint space via a posterior approach in preparation for delivering an implant to the spinal facet joint space.
• 8,828,062: Vertebral joint implants and delivery tools describes a method of implanting a spinal implant in a facet joint.
Providence Medical Technology is a privately held medical device company focused on technology for the cervical spine market. The company’s primary product is the DTRAX platform of differentiated cervical implants and instruments to treat cervical degenerative disc disease through indirect decompression and fusion.
In April, the company closed a $6.8 million round of Series C funding.
“This round of growth capital comes at an exciting time for Providence Medical Technology,” Smith said at the time. “Our U.S. launch is underway, and the surgeon acceptance of indirect decompression and fusion among surgeons who treat cervical radiculopathy has been extremely encouraging. With this investment to support execution of our business plan, we look forward to building a differentiated franchise.”
Providence initiated U.S. surgeon training in November last year following U.S. Food and Drug Administration 510(k) clearance earlier in the year of the DTRAX cervical cage.
“We are proud of our growing patent portfolio protecting our innovative suite of cervical fusion products,” commented Jeff Smith, CEO of Providence Medical Technology. “We believe that our method of accessing the posterior aspect of the cervical spine is unique, and that placement of implants, regardless of design, via this approach is an area of significant differentiation for our product line.”
These new issuances bring the total number of patents issued to Providence to 13.
The patent descriptions are:
• 8,834,530: Cervical distraction method describes a method of implanting an implant in a facet joint, including puncturing an access hole in a facet capsule, accessing the facet joint with a guide tool through the access hole, and routing an implant into the joint along the guide tool.
• 8,834,472: Vertebral joint implants and delivery tools describes a system for minimally invasively accessing a spinal facet joint space via a posterior approach in preparation for delivering an implant to the spinal facet joint space.
• 8,828,062: Vertebral joint implants and delivery tools describes a method of implanting a spinal implant in a facet joint.
Providence Medical Technology is a privately held medical device company focused on technology for the cervical spine market. The company’s primary product is the DTRAX platform of differentiated cervical implants and instruments to treat cervical degenerative disc disease through indirect decompression and fusion.
In April, the company closed a $6.8 million round of Series C funding.
“This round of growth capital comes at an exciting time for Providence Medical Technology,” Smith said at the time. “Our U.S. launch is underway, and the surgeon acceptance of indirect decompression and fusion among surgeons who treat cervical radiculopathy has been extremely encouraging. With this investment to support execution of our business plan, we look forward to building a differentiated franchise.”
Providence initiated U.S. surgeon training in November last year following U.S. Food and Drug Administration 510(k) clearance earlier in the year of the DTRAX cervical cage.